Annual Drug Patent Expirations for ULTIVA Ultiva is a drug marketed by Mylan Institutional and is included in one NDA. It is available from one supplier. There is one patent…
The post New patent expiration for Mylan Institutional drug ULTIVA appe…
New patent expiration for Mylan Institutional drug ULTIVA Read Post »
Annual Drug Patent Expirations for SENSIPAR Sensipar is a drug marketed by Amgen and is included in one NDA. It is available from six suppliers. There are three patents protecting…
The post New patent expiration for AMGEN drug SENSIPAR appeared f…
Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications Driven by patient loyalty, prescriber preference, pharmacist trust, and traditional marketing, branded generics&#…
Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Read Post »
As pharmaceutical companies face ceaseless pressure to expedite products to market, strategies for improving the drug development and manufacturing process gets critical. And all challenges related to drug development start…
The post Optimizing y…
Optimizing your API strategy to deliver desired results Read Post »
SPRITAM (levetiracetam) Aprecia pharms Patent: 9,463,160 Expiration: Feb 20, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or…
Th…
Drug Patent Expirations for the Week of February 18, 2018 Read Post »
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
The post Comparing Generic Dru…
This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…
Contribution of NIH funding to new drug approvals 2010–2016 Read Post »
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for biosimilars in the United States is far more complex than…
The post Understanding the Barriers to US Biosimilars appeared …
Annual Drug Patent Expirations for SOLODYN Solodyn is a drug marketed by Medicis and is included in one NDA. It is available from three suppliers. There are nine patents protecting…
The post New patent expiration for Medicis drug SOLODYN appeared…
Annual Drug Patent Expirations for XIMINO Ximino is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are…
The post New patent expiration for Sun Pharm drug XIMINO appeared first on DrugPat…
Get new actionable insights and updates from BiotechBlog
